SCHEMBL2414732

SCHEMBL2414732

Cc1ccc(N(CCc2csc(SC(C)(C)C(=O)O)n2)Cc2ccc(C(F)(F)F)cc2)nc1

nearest known ligand 0.38

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 5/20 0.38
POLB P06746 1/20 0.37
SLC22A12 Q96S37 2/20 0.37
TP53 P04637 8/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
LMNA P02545 3/20 0.34
PPARG P37231 3/20 0.34
MAPT P10636 2/20 0.34
ALOX5AP P20292 1/20 0.34
PPARD Q03181 2/20 0.33
TRPM8 Q7Z2W7 1/20 0.33
KDM4E B2RXH2 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2417109 0.89 TRPM8 (0.38) ALOX5APTRPM8
SCHEMBL2412764 0.85 PPARA (0.40) PPARAPOLBSLC22A12TP53HDAC1
SCHEMBL2415253 0.82 ERCC5 (0.35) POLBSLC22A12TP53LMNAMAPT
SCHEMBL12274122 0.79 SLC22A12 (0.43) PPARAPOLBSLC22A12TP53LMNA
SCHEMBL12320217 0.78 PPARA (0.38) PPARASLC22A12HDAC1HDAC6
SCHEMBL12274992 0.78 GBA1 (0.35) PPARASLC22A12HDAC1HDAC6
SCHEMBL2407564 0.78 PPARA (0.42) PPARAPOLBSLC22A12TP53HDAC1
Hydrochloric Acid SCHEMBL2419940 0.78 SLC22A12 (0.42) PPARAPOLBSLC22A12TP53LMNA
SCHEMBL2412581 0.78 HDAC1 (0.33) PPARAHDAC1HDAC6
SCHEMBL2412577 0.78 HDAC1 (0.33) PPARAHDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG PPARA 1/4885POLB 3392/4885SLC22A12 920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.